Frontiers in Immunology (Oct 2024)

IL-33-primed human mast cells drive IL-9 production by CD4+ effector T cells in an OX40L-dependent manner

  • Louise Battut,
  • Louise Battut,
  • Edouard Leveque,
  • Edouard Leveque,
  • Salvatore Valitutti,
  • Salvatore Valitutti,
  • Salvatore Valitutti,
  • Nicolas Cenac,
  • Nicolas Cenac,
  • Gilles Dietrich,
  • Gilles Dietrich,
  • Eric Espinosa,
  • Eric Espinosa

DOI
https://doi.org/10.3389/fimmu.2024.1470546
Journal volume & issue
Vol. 15

Abstract

Read online

Interleukin-33 (IL-33) is an alarmin released by epithelial cells in response to tissue damage. It activates resident immune sentinel cells, which then produce signals commonly associated with type 2 immune responses, particularly affecting infiltrating antigen-specific T cells. Given that mast cells (MCs) are a primary target of IL-33 and can shape T helper (Th) cell responses, we investigated the effect of IL-33 priming on the ability of MCs to influence Th cell cytokine production. To examine the Th cell/MC interaction, we developed human primary MC/memory CD4+ T-cell coculture systems involving both cognate and non-cognate interactions. Our results demonstrated that IL-33-primed MCs, whether as bystander cells cocultured with activated effector T cells or functioning as antigen-presenting cells, promoted IL-9 and increased IL-13 production in Th cells via an OX40L-dependent mechanism. This indicates that MCs sense IL-33-associated danger, prompting them to direct Th cells to produce the key type 2 effector cytokines IL-9 and IL-13.

Keywords